Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II StudyGlenn J. Hanna, Jochen H. Lorch, Robert I. Haddad et al.|Clinical Cancer Research|2018Cited by 125
A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).Jochen H. Lorch, David A. Barbie, Justine A. Barletta et al.|Journal of Clinical Oncology|2020Cited by 65
Everolimus in Anaplastic Thyroid Cancer: A Case SeriesEthan Harris, Jochen H. Lorch, Glenn J. Hanna et al.|Frontiers in Oncology|2019Cited by 41